• Industry: Health & Science
  • Type: Equity, P2P lending
  • Min. investment: €100
  • Country: Germany
  • Follow:

Aescuvest

Working here? Claim this profile

Aescuvest is a leading, healthcare dedicated FinTech company, with a special focus on financing digital healthcare solutions. Aescuvest’s mission is to facilitate and enable impactful investments into medical breakthrough innovation to disrupt and improve healthcare delivery models, products, and services. Aescuvest enables its investors to build their very individual portfolio of healthcare start-ups - according to their personal investment focus.

A cooperation with EIT Health, and a growing network of partnerships across Europe, allow Aescuvest to source and evaluate the most promising healthcare investment opportunities, structure their financing rounds, and enable healthcare technology-driven investors, such as Business Angels, HNWIs, Family Offices, and Corporate Investors, to participate in healthcare investment opportunities by direct investments via SPV structures.

The Investment Committee, composed of Aescuvest’s very own investment team and members of the Advisory Board of Aescuvest, both deeply rooted in the healthcare industry and with proven track records, have developed a strong and over the last years well tested, pre-screening and due diligence process, to identify and select healthcare start-ups. Aescuvest’s Management is committing own capital to each company prior introduction to the wider Aescuvest investor base.

The combination of innovative ways for equity capital provision, with healthcare industry and investment expertise, provides the Aescuvest portfolio companies a unique platform to develop their business solution, accelerate their path towards commercialization, and lower market access barriers.

Since inception, Aescuvest has successfully raised 30,5 million Euro for its companies and shows roughly 11 million Euro raised capital in 2021 alone.

Key information

  • Platform Fee N/A
  • Payment Fee N/A
  • Secondary market No
  • Registration number N/A
  • Languages English, German
  • Address Frankfurt am Main, Hessen
  • Who can invest? Personal, Corporate
  • Reviews Check on

Similar companies

The crowdinvesting provider ReaCapital is currently clearly focusing on real estate and enables private investors to make investments from small amounts. With the small amounts, investors...

Koregraf is a French platform exclusively dedicated to crowdfunding real estate. Minimum investment amount is €2,000 with investment duration from 12 to 24 months. Expected profitability ...

InvoiceFair is an innovative trading Platform that gives business access to fast, flexible working capital finance. The company was founded by an experienced team who are passionate about...

Aescuvest is a leading, healthcare dedicated FinTech company, with a special focus on financing digital healthcare solutions. Aescuvest’s mission is to facilitate and enable impactful inv...

Genervest

Verified platform
Netherlands

Genervest is a whole new way to invest ethically and socially. It lets investors – who they call Genervestors – big and small – grow their money while supporting the energy transition. Ge...

Immocratie

Verified platform
France

Immocratie is a crowdfunding platform dedicated to real estate. It invites private investors to finance experienced promoters by providing funds for one of their operations. The transacti...

Switzerland

Cashare is the first disruptive FinTech company in Switzerland, established in January 2008 and has been running the biggest and fastest growing crowdlending platform in this country sinc...

United Kingdom

BrickVest is an online real estate investment platform that directly connects investors with a wide variety of institutional-grade real estate investment opportunities in an easy and tran...


crowdfunding platform survey 2022
Help our research

Participate in our annual survey of crowdfunding platforms in the EU and UK to figure out the state of the industry and help shape its future. All participants will get early access to the report.